Author

Lise Svenningsen

ADALIMUMAB AND INFLIXIMAB CLEARANCE IN NEONATES (ERA STUDY)

Mette Julsgaard, Lisbet Ambrosius Christensen, Peter R. Gibson, Richard Blair Gearry, Jan Fallingborg, jens kjeldsen, Signe Wildt, Lise Svenningsen, William Connell, Christian Lodberg Hvas, Miles P. Sparrow, Alissa Walsh, Susan J. Connor, Graham Radford-Smith, Ian Lawrance, Jane Andrews, Katie Ellard, Ourania Rosella, Ann

IS FECAL CALPROTECTIN THE BETTER TOOL TO MONITOR DISEASE ACTIVITY IN PREGNANT IBD PATIENTS?

Mette Julsgaard, Lisbet Ambrosius Christensen, Christian Lodberg Hvas, Jan Fallingborg, Lise Svenningsen, jens kjeldsen, Miles P. Sparrow, Signe Wildt, Sally J. Bell

TIME SINCE LAST DRUG EXPOSURE IN PREGNANCY DETERMINES ADALIMUMAB AND INFLIXIMAB LEVELS IN NEONATES (ERA STUDY)

Mette Julsgaard, Lisbet Ambrosius Christensen, Peter R. Gibson, Jan Fallingborg, Richard Blair Gearry, Miles P. Sparrow, Jane Andrews, Susan J. Connor, Ian Lawrence, Signe Wildt, Gregory Moore, Lise Svenningsen

VEDOLIZUMAB LEVELS IN MOTHERS AND NEWBORNS, CLEARANCE IN NEONATES, SUSCEPTIBILITY TO INFECTION, AND ACHIEVEMENT OF DEVELOPMENTAL MILESTONES

Mette Julsgaard, Daniel C. Baumgart, Simon Mark Dahl Jørgensen, Mette Mejlby Hansen, Anne Grosen, jens kjeldsen, Heidi Gram Sørensen, Lone Larsen, Signe Wildt, Petra Weimers, Kent Valentin Haderslev, Ida Vind, Lise Svenningsen, Jørn Brynskov, Søren Lyhne, Thea Vestergaard, Christian Lodberg Hvas, Jens Kelsen

Item 1 - 4 / 4
1